Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?

J Surg Oncol. 2010 Dec 15;102(8):922-31. doi: 10.1002/jso.21727.

Abstract

Surgical resection offers the best chance for cure in patients with colorectal liver metastases; however, only 15-25% of them can benefit from surgery. To increase resectability a number of strategies have been developed in different fields including chemotherapy, surgery, and radiology. Bringing them together into an integrated framework has expanded the number of patients that can be treated with curative intent. This review focuses on recent oncosurgical changes, their impact, and future directions.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / surgery
  • Hepatectomy
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Liver Neoplasms / therapy
  • Neoadjuvant Therapy* / adverse effects
  • Neoplasm Staging
  • Reoperation

Substances

  • Antineoplastic Agents